6 results
RIPE Therapy - Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis - IDSA Guidelines

#Tuberculosis #ActiveTB #RIPE #Therapy
RIPE Therapy - Drug ... Confirmed Pulmonary ... #ActiveTB #RIPE ... #medications #pharmacology ... IDSA #Guidelines #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
inhibitors • Injection drug ... Diagnosis: Latent ... Treatment: Active ... #TB #Diagnosis ... #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
inhibitors • Injection drug ... Diagnosis: Latent ... Treatment: Active ... #TB #Diagnosis ... #Management #Treatment
Treatment Options for Helicobacter Pylori and Peptic Ulcer Disease

Active Helicobacter pylori—associated ulcer
1. Treat with anti—H pylori
Ulcer Disease Active ... anti—H pylori regimen ... the preferred drugs ... #Management #Pharmacology ... #Medications
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
Mycobacterium Tuberculosis ... RAL-based ART regimen ... and molecular diagnostic ... #management #opportunistic ... infections #HIVAIDS #pharmacology
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
, INC risk PE, Pulmonary ... Adenocarcinoma Treatment ... lubricants • Pharmacologic ... muscarinic agonists • Active ... #Management